Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
详细信息 查看全文
- 作者：Paolo Anderlini1 ; panderli@mdanderson.org" class="auth_mail" title="E-mail the corresponding author ; Rima M. Saliba1 ; Celina Ledesma1 ; Tamera Plair1 ; Amin M. Alousi1 ; Chitra M. Hosing1 ; Issa F. Khouri1 ; Yago Nieto1 ; Uday R. Popat1 ; Elizabeth J. Shpall1 ; Michelle A. Fanale2 ; Frederick B. Hagemeister2 ; Yasuhiro Oki2 ; Saatva Neelapu2 ; Jorge E. Romaguera2 ; Anas Younes3 ; Richard E. Champlin1
- 关键词：Hodgkin lymphoma ; Allogeneic stem cell transplantation ; Bone marrow transplantation ; Brentuximab vedotin
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：22
- 期：7
- 页码：1333-1337
- 全文大小：167 K
文摘
- listitem" id="list_ulist0010">
- •
The optimal preparative regimen for allogeneic transplantion in Hodgkin lymphoma is unknown.
- •
We added gemcitabine to our standard fludarabine–melphalan combination (G-FM).
- •
The G-FM regimen allowed moderate dose intensification with acceptable toxicity.